Immunotherapy of melanoma.

Contemporary oncology (Poznan, Poland) Pub Date : 2018-03-01 Epub Date: 2018-03-05 DOI:10.5114/wo.2018.73889

Iwona Lugowska, Pawel Teterycz, Piotr Rutkowski

{"title":"Immunotherapy of melanoma.","authors":"Iwona Lugowska, Pawel Teterycz, Piotr Rutkowski","doi":"10.5114/wo.2018.73889","DOIUrl":null,"url":null,"abstract":"<p><p>The immunotherapy is currently changing the landscape of oncology. Nowadays the standard of care in metastatic or unresectable melanoma patients include immunomodulating modalities such as anti-PD-1 drugs (nivolumab, pembrolizumab) and anti-CTLA-4 antibody ipilimumab. The improvements of progression free survival and overall survival connected with those treatments were unprecedented and have been confirmed in stage III trials. The efficacy of immunotherapy in metastatic setting can be further upgraded in some groups of patients by combining both types of antibodies. Latest clinical data suggest that treatment with immunotherapy can be also favorable for patients in adjuvant setting. Other treatment approaches based on immunological response (e.g. oncolytic viruses or adoptive cell therapy) have been proven useful in specific clinical situations. The future of melanoma treatment is still evolving, new molecular targets are being invented and hopefully current endeavors will led to further improvement of patients' survival. This review aims to summarize current state of immunotherapy in melanoma and identifying possible directions of development.</p>","PeriodicalId":520599,"journal":{"name":"Contemporary oncology (Poznan, Poland)","volume":" ","pages":"61-67"},"PeriodicalIF":0.0000,"publicationDate":"2018-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5114/wo.2018.73889","citationCount":"48","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contemporary oncology (Poznan, Poland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/wo.2018.73889","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/3/5 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 48

Abstract

The immunotherapy is currently changing the landscape of oncology. Nowadays the standard of care in metastatic or unresectable melanoma patients include immunomodulating modalities such as anti-PD-1 drugs (nivolumab, pembrolizumab) and anti-CTLA-4 antibody ipilimumab. The improvements of progression free survival and overall survival connected with those treatments were unprecedented and have been confirmed in stage III trials. The efficacy of immunotherapy in metastatic setting can be further upgraded in some groups of patients by combining both types of antibodies. Latest clinical data suggest that treatment with immunotherapy can be also favorable for patients in adjuvant setting. Other treatment approaches based on immunological response (e.g. oncolytic viruses or adoptive cell therapy) have been proven useful in specific clinical situations. The future of melanoma treatment is still evolving, new molecular targets are being invented and hopefully current endeavors will led to further improvement of patients' survival. This review aims to summarize current state of immunotherapy in melanoma and identifying possible directions of development.

查看原文本刊更多论文

黑色素瘤的免疫治疗。

免疫疗法目前正在改变肿瘤学的格局。目前，转移性或不可切除黑色素瘤患者的标准治疗包括免疫调节方式，如抗pd -1药物(nivolumab, pembrolizumab)和抗ctla -4抗体易普利姆单抗。与这些治疗相关的无进展生存期和总生存期的改善是前所未有的，并已在III期试验中得到证实。通过结合两种类型的抗体，在某些组的患者中，转移性免疫治疗的疗效可以进一步提高。最新的临床数据表明，免疫治疗也可以有利于患者的辅助设置。其他基于免疫反应的治疗方法(如溶瘤病毒或过继细胞疗法)已被证明在特定临床情况下有用。黑色素瘤治疗的未来仍在发展，新的分子靶点正在被发明，希望目前的努力将导致进一步改善患者的生存。本文综述了黑色素瘤免疫治疗的现状，并探讨了可能的发展方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Contemporary oncology (Poznan, Poland)

自引率

0.00%

发文量